Rilonacept Reduces Gout Flares During Acute Urate Lowering Rx

Phase 2 trial shows that rilonacept reduces gout flares during initiation of allopurinol therapy

MONDAY, Jan. 9 (HealthDay News) -- The use of rilonacept significantly reduces gout flare-ups in the first few months following initiation of urate-lowering therapy (ULT), according to research published online Jan. 4 in Arthritis & Rheumatism.

H. Ralph Schumacher Jr., M.D., of the University of Pennsylvania and VA Medical Center in Philadelphia, and colleagues conducted a randomized, double-blind, 16-week, phase 2 clinical trial, in which 42 participants received placebo and 41 participants received rilonacept (loading dose 320 mg followed by 160 mg weekly). The predominantly white, non-Hispanic male participants (mean age of 51 years) received 300 mg/day of allopurinol, titrated to serum urate <6 mg/dL. Flare-ups were self-reported by patients via an interactive telephone voice response system.

During a 12-week period, the researchers observed an average of 0.15 acute gout flares per patient in those receiving rilonacept, compared with 0.79 flare-ups per patient in those receiving placebo. Only 14.6 percent of patients receiving rilonacept experienced one or more gout attacks during ULT, while 45.2 percent of those on placebo suffered flare-ups. Adverse events were similar between the two groups.

"Prevention of gout flares with an agent that has an acceptable safety and tolerability profile could potentially contribute to increased long-term adherence with ULT and thus better maintenance of reduced serum urate levels and better disease control," the authors write. "Further evaluation of rilonacept in this disease is warranted, for both prevention and treatment of acute flares."

The study was funded by Regeneron Pharmaceuticals Inc., the manufacturer of rilonacept; several authors disclosed financial relationships with pharmaceutical companies, including Regeneron.

Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Powered by

jQuery UI Accordion - Default functionality

For life-long learning and continuing professional development, come to Lippincott's NursingCenter.

Nursing Jobs Plus
Featured Jobs
Recommended CE Articles

Blunt Chest Trauma
Journal of Trauma Nursing, November/December 2014
Expires: 12/31/2016 CE:2 $21.95

The School Age Child with Congenital Heart Disease
MCN, The American Journal of Maternal/Child Nursing, January/February 2015
Expires: 2/28/2017 CE:2.5 $24.95

Understanding multiple myeloma
Nursing Made Incredibly Easy!, January/February 2015
Expires: 2/28/2017 CE:2 $21.95

More CE Articles

Subscribe to Recommended CE

Recommended Nursing Articles

Comprehensive Care: Looking Beyond the Presenting Problem
Journal of Christian Nursing, January/March 2015
Free access will expire on March 2, 2015.

Pain and Alzheimer dementia: A largely unrecognized problem
Nursing Made Incredibly Easy!, January/February 2015
Free access will expire on February 16, 2015.

Glycemic control in hospitalized patients
Nursing2015 Critical Care, January 2015
Free access will expire on February 16, 2015.

More Recommended Articles

Subscribe to Recommended Articles

Evidence Based Practice Skin Care Network NursingCenter Quick Links What’s Trending Events